Frontera’s Study Report on ” Case Studies of Resolving rAAV Aggregation & Removing Empty Vectors ” will be presented in Gene Therapy for Rare Disorders 2024

Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been invited to deliver a presentation focusing on the vital topic of “Case Studies: Overcoming Challenges in rAAV Drug Manufacturing.” on March 27, 2024. This presentation falls within the Manufacturing category and will delve into two pivotal case studies aimed at resolving common manufacturing hurdles encountered in purifying rAAV drugs.

The first case study will explore innovative strategies for mitigating rAAV aggregates, while the second will delve into methodologies for effectively removing empty vectors, resulting in less than 1% in the final drug substance.

Frontera extends a warm invitation to all conference attendees to join Dr. Lu’s presentation and actively participate in the discussions.